METTL3 and acute myeloid leukemia: Due to the oncogenic role of the m6A methyltransferase (MTase) METTL3, targeting the m6A epitranscriptome by pharmacological inhibition of enzymes controlling m6A homeostasis including METTL3 represents a promising strategy for treating acute myeloid leukemia (AML) and likely other cancer types13,14.